Pislocybin vs Ketamin vs MDA

Mechanisms of Action

These compounds act on different primary targets in the brain, which helps explain differences in acute effects and proposed therapeutic pathways.

Psilocybin is a classic serotonergic psychedelic. After conversion to psilocin in the body, it primarily acts as an agonist at the 5-HT2A serotonin receptor. Research links this activity to temporary disruption of the default mode network, increased cortical entropy, and downstream promotion of neuroplasticity. The acute experience often includes perceptual changes, emotional intensification, and shifts in sense of self that last several hours.

Ketamine is a dissociative anesthetic that functions mainly as an NMDA receptor antagonist in the glutamate system. This leads to a cascade involving AMPA receptor activation, BDNF release, and rapid synaptic remodeling, particularly in regions involved in mood regulation. Effects onset quickly and the acute dissociative state is typically shorter than with classic psychedelics. Esketamine, the S-enantiomer delivered as a nasal spray (Spravato), has specific regulatory approval for certain depression indications.

MDA is structurally related to MDMA and historically described as having both empathogenic and more pronounced psychedelic properties. Comparative human studies indicate MDA produces longer-lasting effects, stronger stimulant-like and visual alterations, and a higher incidence of negative subjective effects (such as fear) relative to MDMA at comparable doses. It engages monoamine systems and has 5-HT2A activity contributing to its psychedelic character, but modern clinical therapy research on MDA itself remains limited compared with MDMA or the other two compounds discussed here.

All three can influence neuroplasticity and emotional processing in research settings, yet the pathways and time courses differ.

Therapeutic Research Focus and Evidence

Ketamine has the most established clinical footprint for psychiatric use. Multiple randomized trials and meta-analyses dating back more than two decades support rapid antidepressant effects, often within hours, in treatment-resistant depression (TRD). Esketamine received FDA approval for TRD (in conjunction with an oral antidepressant) and is administered under medical supervision. Protocols commonly involve an induction series of sessions followed by maintenance. The evidence base is larger and more mature than for the others.

Psilocybin has generated strong interest through trials for major depressive disorder, treatment-resistant depression, end-of-life anxiety, and certain substance-use disorders. Notable studies (including work associated with Johns Hopkins, Imperial College London, and COMPASS Pathways) have reported substantial symptom reductions, sometimes after one or two supervised sessions, with effects lasting weeks to months in responders. As of late 2026, no FDA-approved psilocybin product for psychiatric indications exists in the United States, though some state-regulated programs (Oregon and Colorado) permit supervised adult use under specific frameworks, and research continues.

MDA lacks a comparable contemporary clinical development program for mental health indications. Earlier historical psychotherapy exploration occurred, and modern pharmacological studies in healthy volunteers have characterized its effects relative to MDMA. Those studies suggest a profile with more psychedelic and adverse elements that may be less favorable for the empathogenic, trauma-focused work currently associated with MDMA-assisted therapy research. MDMA itself (not MDA) has advanced through Phase 3 trials for PTSD, though regulatory outcomes have included requests for additional data.

Head-to-head comparisons between psilocybin and ketamine remain limited; most evidence is indirect. Both can produce meaningful antidepressant signals, but differences in onset speed, durability after single versus repeated dosing, and the role of the subjective experience continue to be investigated.

How Therapy Models Differ in Research Settings

In clinical research, these substances are typically paired with psychological support rather than used in isolation.

Psilocybin studies often emphasize preparation sessions, a full-day dosing session (commonly 6–8 hours including monitoring), and structured integration afterward. The longer duration and intensity of the experience are considered part of the therapeutic process for some conditions.

Ketamine protocols are generally shorter (often 1–2 hours per session). Medical monitoring is central, and the treatment course frequently involves multiple administrations because antidepressant effects tend to wane without maintenance. Psychotherapy may be incorporated (sometimes called ketamine-assisted psychotherapy), but the pharmacological effect itself is rapid and does not always require the same extended experiential framework used with classic psychedelics.

MDA has not been studied in the same structured, multi-session psychotherapy models that characterize recent psilocybin or MDMA research. Available human data focus more on acute pharmacology and subjective effects than on standardized therapeutic protocols.

Across all cases, research protocols include screening for contraindications (cardiovascular, psychiatric history, medication interactions), continuous supervision during acute effects, and follow-up. These safeguards are central to the published safety profiles.

Legal and Access Differences

Ketamine (Schedule III in the U.S.) can be prescribed by licensed clinicians for approved or off-label uses within medical practice. Esketamine has specific FDA labeling and REMS requirements.

Psilocybin remains Schedule I at the federal level in the United States, restricting it primarily to research or limited state programs. International regulatory status varies.

MDA is a Schedule I controlled substance in the U.S. and most jurisdictions, with no approved medical pathway comparable to ketamine and far less clinical infrastructure than either ketamine or the more advanced MDMA research programs.

Access, cost, insurance coverage, and legal risk therefore differ substantially.